Company analytics
MGXIndustry: Biological Products, (No Diagnostic Substances)Fiscal year ends 31 Dec
Annual figures computed from the company's XBRL filings. Each point is one fiscal year.
| Company | Fiscal year | Value |
|---|---|---|
| Revenue | FY2024 | $52.3M |
| Revenue | FY2025 | $25.2M |
Only one year is available (FY2025: -51.8%).
| Company | Fiscal year | Value |
|---|---|---|
| Operating margin | FY2024 | -170.0% |
| Operating margin | FY2025 | -380.9% |
| Company | Fiscal year | Value |
|---|---|---|
| Net margin | FY2024 | -149.3% |
| Net margin | FY2025 | -348.5% |
What the company reports its revenue came from.
Segment analytics unavailable for this company in the current structured data layer
Product, segment and geographic revenue are not tagged in the company’s processed filings, or could not be mapped. No mix is estimated and no chart is drawn.
Compared with other biological products, (no diagnostic substances) companies in the structured data layer.
Fewer than 5 peers in the same SIC industry report these metrics, so no percentile position is shown. (6 peers in the industry.)
Share of the other covered companies (any industry) whose latest value is lower. Each company's own latest fiscal year; industries differ, so this is context, not a peer ranking.
The largest other companies in the same industry, by revenue.
| Company | Revenue | Growth | Operating margin | Net margin |
|---|---|---|---|---|
| Voyager Therapeutics, Inc. | $40.4M | -49.5% | -326.6% | -296.5% |
| MICROMET, INC. | $21.9M | -23.7% | -372.1% | -338.4% |
| VBI VACCINES INC. | $396.0K | — | -3322.5% | -3509.4% |
Annual reports in the structured data layer.